|
|
 |
|
Viewing report
|
|
|
|
The State of Biomarkers in Clinical Development
Industry Standard Research (ISR), June 2010, Pages: 47
This innovative report focuses on interviews with 44 biomarkers specialists from 37 different biopharma companies. Participants provide views to their biomarkers strategies, experiences and predictions for their adoption in drug development. Specifically, the report details pharma companies, current and future adoption of 6 different types of biomarkers including: Diagnostic Biomarkers, Early Detection / Screening Biomarkers, Predictive Biomarkers, Prognostic Biomarkers, Surrogate Biomarkers and Toxicity Biomarkers.
The report also reveals pharma companies; current and future adoption of many specific biomarkers technologies including: Bioinformatics and Systems Biology, Genomics, Glycomics, Histomics, Imaging, Metabolomics, and Proteomics. Further, this research uncovers the proportion of products within respondents pipelines that contain biomarker strategies and the stages at which biomarker strategies are developed for products. Respondents also discuss their development strategies for products with biomarkers.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
